Logomix Inc. ^None

Logomix Inc. is a synthetic biology company that has developed a genome engineering platform called Geno-Writing™. This platform allows for precise manipulation of genomic sequences within human cells on a large scale. The company is focused on developing hypoimmune cells for cell therapy and addressing limitations in current approaches. Logomix also aims to unlock the potential of treating solid tumors and genetic diseases, which is worth trillions of dollars.